Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (11)

2024

  1. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

    Blood, Vol. 143, Núm. 18, pp. 1807-1815

  2. Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)

    American Journal of Hematology

2023

  1. An update on the pathogenesis and diagnosis of thrombotic thrombocytopenic purpura

    Expert Review of Hematology, Vol. 16, Núm. 1, pp. 17-32

  2. Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)

    Journal of Clinical Medicine, Vol. 12, Núm. 20

2022

  1. COVID-19 Vaccines and Autoimmune Hematologic Disorders

    Vaccines, Vol. 10, Núm. 6

  2. Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era

    Annals of Hematology, Vol. 101, Núm. 1, pp. 59-67

  3. Novel Therapies to Address Unmet Needs in ITP

    Pharmaceuticals, Vol. 15, Núm. 7

  4. Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura

    Medicina Clinica, Vol. 158, Núm. 12, pp. 630.e1-630.e14

2021

  1. Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura

    Journal of Clinical Apheresis, Vol. 36, Núm. 4, pp. 563-573

2015

  1. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

    American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43

  2. Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia

    Platelets, Vol. 26, Núm. 1, pp. 83-86